Effect of increasing oral doses of loperamide on gallbladder motility in man
- PMID: 2297461
- PMCID: PMC1380061
- DOI: 10.1111/j.1365-2125.1990.tb03602.x
Effect of increasing oral doses of loperamide on gallbladder motility in man
Abstract
1. Loperamide, a peripherally acting opiate receptor agonist with antidiarrhoeal action, inhibits ileal and colonic motor function. To determine the effect of loperamide on gallbladder motility, we have pretreated five healthy volunteers with 2 mg oral loperamide 24 h, 20, 12 and 2.5 h before; six healthy volunteers with 16 mg oral loperamide 2.5 h before; and eight healthy volunteers with 16 mg oral loperamide 12 and 2.5 h before intravenous infusion of a 'physiological dose' of 12.5 pmol kg-1 cholecystokinin (CCK) for 1 h to stimulate gallbladder contraction. All subjects served as their own controls. Gallbladder volume was measured by ultrasonography and plasma CCK by radioimmunoassay until 90 min after start of the CCK infusion. 2. Infusion of CCK resulted in plasma CCK concentrations similar to those after intraduodenal fat. Integrated gallbladder contraction after 4 X 2 mg loperamide (4600 +/- 891% min) was similar to that without pretreatment (5270 +/- 1037% min; NS). Integrated gallbladder contraction after 1 X 16 mg loperamide diminished from 5458 +/- 412% min without to 2632 +/- 816% min with loperamide (P less than 0.05), and was completely abolished to -596 +/- 762% min (P less than 0.0005 vs without loperamide) after 2 X 16 mg loperamide. 3. It is concluded that loperamide inhibits gallbladder contraction in response to a physiological dose of cholecystokinin in a dose-dependent manner.
Similar articles
-
mu-Opiate receptor agonist loperamide blocks bethanechol-induced gallbladder contraction, despite higher cholecystokinin plasma levels in man.Neurogastroenterol Motil. 2005 Oct;17(5):761-6. doi: 10.1111/j.1365-2982.2005.00694.x. Neurogastroenterol Motil. 2005. PMID: 16185316
-
Inhibition of pancreaticobiliary secretion by loperamide in humans.Hepatology. 1997 Aug;26(2):256-61. doi: 10.1002/hep.510260201. Hepatology. 1997. PMID: 9252131 Clinical Trial.
-
Inhibitory effect of atropine on cholecystokinin-induced gallbladder contraction in man.Digestion. 1984;29(4):209-13. doi: 10.1159/000199035. Digestion. 1984. PMID: 6468768 Clinical Trial.
-
Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide.Am J Physiol. 1991 Feb;260(2 Pt 1):G197-206. doi: 10.1152/ajpgi.1991.260.2.G197. Am J Physiol. 1991. PMID: 1996640
-
Factors affecting gallbladder motility: drugs.Dig Liver Dis. 2003 Jul;35 Suppl 3:S17-9. doi: 10.1016/s1590-8658(03)00088-4. Dig Liver Dis. 2003. PMID: 12974504 Review.
Cited by
-
Sphincter of Oddi Function and Risk Factors for Dysfunction.Front Nutr. 2017 Jan 30;4:1. doi: 10.3389/fnut.2017.00001. eCollection 2017. Front Nutr. 2017. PMID: 28194398 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous